Home/Filings/4/0001209191-20-029401
4//SEC Filing

Bozigian Haig P. 4

Accession 0001209191-20-029401

CIK 0000914475other

Filed

May 13, 8:00 PM ET

Accepted

May 14, 8:09 PM ET

Size

25.5 KB

Accession

0001209191-20-029401

Insider Transaction Report

Form 4
Period: 2020-05-12
Bozigian Haig P.
Sr Vice President, Development
Transactions
  • Exercise/Conversion

    Common Stock

    2020-05-12$35.99/sh+9,094$327,293157,727 total
  • Sale

    Common Stock

    2020-05-12$114.94/sh9,094$1,045,303148,633 total
  • Exercise/Conversion

    Common Stock

    2020-05-12$43.24/sh+18,571$803,010167,204 total
  • Sale

    Common Stock

    2020-05-12$114.94/sh18,571$2,134,631148,633 total
  • Exercise/Conversion

    Common Stock

    2020-05-12$81.49/sh+15,833$1,290,231164,466 total
  • Sale

    Common Stock

    2020-05-12$114.94/sh15,833$1,819,913148,633 total
  • Exercise/Conversion

    Common Stock

    2020-05-12$81.05/sh+18,057$1,463,520166,690 total
  • Sale

    Common Stock

    2020-05-12$114.94/sh18,057$2,075,549148,633 total
  • Exercise/Conversion

    Non-Qualified Stock Option

    2020-05-129,0940 total
    Exercise: $35.99Exp: 2026-02-05Common Stock (9,094 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option

    2020-05-1218,57115,289 total
    Exercise: $43.24Exp: 2027-02-06Common Stock (18,571 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option

    2020-05-1215,83313,340 total
    Exercise: $81.49Exp: 2028-02-05Common Stock (15,833 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option

    2020-05-1218,05747,383 total
    Exercise: $81.05Exp: 2029-02-07Common Stock (18,057 underlying)
Footnotes (6)
  • [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  • [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]Option granted February 05, 2016 and vested monthly over four years.
  • [F4]Option granted February 06, 2017 and vests monthly over four years.
  • [F5]Option granted February 05, 2018 and vests monthly over four years.
  • [F6]Option granted February 07, 2019 and vests monthly over four years.

Issuer

NEUROCRINE BIOSCIENCES INC

CIK 0000914475

Entity typeother

Related Parties

1
  • filerCIK 0001423837

Filing Metadata

Form type
4
Filed
May 13, 8:00 PM ET
Accepted
May 14, 8:09 PM ET
Size
25.5 KB